- Inhibitors
- Antibodies
- Compound Libraries
- New Products
- Contact Us
research use only
Cat.No.E1068
| Related Targets | Akt Wnt/beta-catenin HSP PKC ROCK Integrin Bcr-Abl Actin FAK Kinesin |
|---|---|
| Other Microtubule Associated Inhibitors | Nocodazole MMAF Patupilone (Epothilone B) Lexibulin (CYT997) CW069 Combretastatin A4 ABT-751 (E7010) Epothilone A Cucurbitacin B TAI-1 |
|
In vitro |
Water : 3 mg/mL
DMSO
: Insoluble
Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 853.91(Only for Paclitaxel) | Formula | C47H51NO14 |
Storage (From the date of receipt) | Store at room temperature, 3 years |
|---|---|---|---|---|---|
| CAS No. | -- | Storage of Stock Solutions | Solutions are unstable. Prepare fresh or purchase small, pre-packaged sizes. Repackage upon receipt. | ||
| In vitro |
Treating human pancreatic ductal adenocarcinoma cells first with gemcitabine followed by Nab-Paclitaxel at 48 hours is found to have the greatest inhibition of cell growth. |
|---|---|
| In vivo |
In mice with human pancreatic cancer xenografts, nab-paclitaxel alone and in combination with gemcitabine deplete the desmoplastic stroma. The intratumoral concentration of gemcitabine is increased by 2.8-fold in mice receiving nab-paclitaxel plus gemcitabine versus those receiving gemcitabine alone. |
References |
|
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT04715542 | Not yet recruiting | Chemotherapy Induced Peripheral Neuropathy (CIPN) |
University of Bern|Insel Gruppe AG University Hospital Bern|Hospital of Thun|Tumor- und Brustzentrum ZeTuP St.Gallen|Gesundheitszentrum Fricktal AG|Kantonsspital Winterthur KSW|Kantonsspital Graubünden|Kantonsspital Aarau |
August 2024 | Phase 3 |
| NCT06199466 | Recruiting | Metastatic Pancreatic Cancer |
M.D. Anderson Cancer Center|280Bio Inc |
January 22 2024 | Phase 1 |
| NCT06059001 | Recruiting | Metastatic Pancreatic Cancer |
Peptomyc S.L. |
August 31 2023 | Phase 1 |
| NCT05982522 | Not yet recruiting | Solid Tumor |
InxMed (Shanghai) Co. Ltd. |
August 2023 | Phase 1|Phase 2 |
| NCT05562297 | Not yet recruiting | Pancreatic Cancer Stage IB|Pancreatic Cancer Stage IIA|Pancreatic Cancer Stage IIB|Pancreatic Cancer Stage III |
Shanghai Zhongshan Hospital|Fudan University |
July 1 2023 | Phase 2 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.